lower price Exenatide acetate（141732-76-5） supply CAS NO.141732-76-5

Min.Order: 1 Gram
Payment Terms: L/C,D/A,D/P,T/T,Other

Product Details

Keywords

Exenatide acetate
141732-76-5
C186H284N50O62S

Quick Details

ProName: lower price Exenatide acetate（141732-...
CasNo: 141732-76-5
Molecular Formula: C186H284N50O62S
Appearance: white powder
Application: used for research
DeliveryTime: 3 days
PackAge: aluminum foil bag
Port: shenzhen
ProductionCapacity: 1 Metric Ton/Day
Purity: 99%min
Storage: Store in cool, dry, ventilated place
Transportation: by sea or by air
LimitNum: 1 Gram
Related Substances: N/A
Residue on Ignition: N/A
Heavy Metal: N/A
Valid Period: one year
N/A: N/A

Superiority

www.wolcase.com

1. Best prices with satisfied quality;

2. It's clients' right to choose the package's Courier (EMS, DHL, FedEx, UPS);

3.It's clients' right to choose the packing way for his produccts from many recent effective packing ways;

4.Specials are possible when client's order is big enough, including the discount policy;

5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;

6.We can help our regular clients to suggest some vials factories which produce different size vials(2ml, 5ml, 7ml, 10ml, 20ml...), hoping can bring you convenience if you need these vials, too.

Details

Exenatide Acetate

product Name Exenatide acetate
Synonyms enfuvirtide acetate; His-Gly-Gly-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH{2}; ExenatideAcetate
Molecular Formula C184H282N50O60S C2H4O2
Molecular Weight 4262.67
CAS Registry Number 141732-76-5
Exenatide, an incretin mimic peptide comprised of 39 amino acid residue, is a new antidiabetic drug approved by FDA in 2005 for the treatment of diabetes mellitus type 2.

The main physiological functions are followings: Promote insulin excretion in glucose-dependence manner, restoration of glucose sensitivity to the islets, inhibition of apoptosis of existing cells and increase the number of β Cells, inhibition of gastric emptying leads to decreased food intake and reduced body weight. The exenatide therapy has the following advantages to compare with insulin therapy: No hypoglycemia effect, reducing body weight, improving insulin resistance, promoting islets cell function of patients.

Exenatide is developed and marketed (brand name Byetta) by Amylin Pharmaceuticals and Eli Lilly and Company. Due to some historical reasons, there is no compound patent for the drug in many countries. The API of the drug and generics have been developed and currently under clinical trial in China. Beyel Pharmaceutical is capable of manufacturing Exenatide Acetate by solid phase synthesis under GMP compliance

lower price Exenatide acetate（141732-76-5） supply CAS NO.141732-76-5

Keywords

Quick Details

Superiority

Details

Other products of this supplier